Skip to main content

Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients

Abstract

Background

Notable fungal coinfections with SARS-CoV-2 in COVID-19 patients have been reported worldwide in an alarming way. Mucor spp. and Rhizopus spp. were commonly known as black fungi, whereas Aspergillus spp. and Candida spp. were designated as white fungi implicated in those infections. In this review, we focused on the global outbreaks of fungal coinfection with SARS-CoV-2, the role of the human immune system, and a detailed understanding of those fungi to delineate the contribution of such coinfections in deteriorating the health conditions of COVID-19 patients based on current knowledge.

Main body

Impaired CD4 + T cell response due to SARS-CoV-2 infection creates an opportunity for fungi to take over the host cells and, consequently, cause severe fungal coinfections, including candidiasis and candidemia, mucormycosis, invasive pulmonary aspergillosis (IPA), and COVID-19-associated pulmonary aspergillosis (CAPA). Among them, mucormycosis and CAPA have been reported with a mortality rate of 66% in India and 60% in Colombia. Moreover, IPA has been reported in Belgium, Netherlands, France, and Germany with a morbidity rate of 20.6%, 19.6%, 33.3%, and 26%, respectively. Several antifungal drugs have been applied to combat fungal coinfection in COVID-19 patients, including Voriconazole, Isavuconazole, and Echinocandins.

Conclusion

SARS-CoV-2 deteriorates the immune system so that several fungi could take that opportunity and cause life-threatening health situations. To reduce the mortality and morbidity of fungal coinfections, it needs immunity boosting, proper hygiene and sanitation, and appropriate medication based on the diagnosis.

Background

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which is spread by human-to-human close contact, especially through respiratory droplets [1]. COVID-19 is a flu-like disease, bearing no symptoms in most infected individuals, but may develop signs and cause acute respiratory distress syndrome (ARDS), pneumonia, and even death [2]. Moreover, it is not only limited to respiratory illness but also has consequences for renal, hematological, and central nervous system (CNS) and develops a severe disease in older individuals and those with underlying medical conditions, including obesity [3], hypertension [4], rheumatic diseases [5], and diabetes mellitus [6, 7]. The intensity of mutation in spike proteins results in more powerful variants of SARS-CoV-2 such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) [8], B.1.621 (Mu) [9], and B.1.1.529 (Omicron) [10] which could weaken the human immune system robustly. According to a retrospective cohort study, the individuals infected with alpha, beta, gamma, and delta variants have an elevated hospitalization risk compared to those infected with progenitor SARS-CoV-2 variants [11]. Because of prolonged hospitalization, the weakened immune system unleashes pathogens, mainly opportunistic fungi, which leads to the impairment of organs and even death [12].

However, there are tens of thousands of recognized fungi in nature, and among them, over 300 fungal species have been identified as human pathogens. Most fungal infections are caused by opportunistic fungi such as Aspergillus, Candida, Cryptococcus, and Pneumocystis [13]. In the case of COVID-19, patients with ARDS, hospitalized in intensive care units (ICU), receiving broad-spectrum antibiotics, going through invasive or noninvasive ventilation, and undergoing immunosuppressive or corticosteroid therapies are at the highest risk of getting opportunistic fungal infections [14]. Fungi responsible for these emerging coinfections, including Mucor spp. and Rhizopus spp., are named black fungi, whereas Aspergillus spp. and Candida spp. are called white fungi [15].

Furthermore, such fungal attacks caused reducing the number of CD4 + and CD8 + T cells resulting in disruption of the adaptive immune system in individuals infected with SARS-CoV-2 [12]. Basically, fungi are destroyed by CD4 + T cell-mediated adaptive immune responses, which protect cells from fungal attack through the action of IFN-γ from T helper cell 1 (Th1) or Interleukin-17 (IL-17) from Th17 cell. As the SARS-CoV-2 infected individuals have disrupted adaptive immune responses, the fungal infection takes over without any interference [16]. Moreover, the innate immune system also gets hampered by the “cytokine storm” due to ARDS and fails to give protection against the fungal pathogen [17].

Given the emphasis on the detrimental effects of fungal coinfections with SARS-CoV-2 in COVID-19 patients, this review study gathers facts and findings to delineate the worldwide notable fungal coinfections; roles of the immune system in the infections; morphological features, pathogenesis, clinical results, and laboratory diagnosis; and control and prevention of those fungi to deliver a comprehensive overview.

Main text

Fungi involved in creating coinfection with SARS-CoV-2

Several fungal diseases have been documented with SARS-CoV-2 infections, including mucormycosis, COVID-19-associated invasive pulmonary aspergillosis (CAPA), invasive candidiasis, and pneumocystis pneumonia [18,19,20,21]. The etiologic agents of mucormycosis are Rhizopus arrhizus, Rhizomucor pusillus, Apophysomyces variabilis, and Lichtheimia corymbifera [22], whereas Aspergillus fumigatus and Aspergillus flavus were predominant in CAPA [18, 23,24,25]. Besides, several Candida spp. such as C. albicans, C. tropicalis, and C. parapsilosis have been reported in invasive candidiasis [18]. Contrarily, pneumocystis pneumonia caused by Pneumocystis jirovecii has been documented in rare occurrences [18, 26]. Understanding the structure, pathogenicity, clinical sign symptoms, and laboratory diagnosis of those fungi would be helpful to outline their contribution to worsening the health conditions of COVID-19 patients (Table 1). There are many symptoms shared by Mucor and Rhizopus infections, such as chest pain, dyspnea, fever, headaches, tiredness, coughing, blisters on the skin, and a stomachache. The diagnosis varies, except for the similarity in a computed tomography scan’s result [27]. The morphologic features of Mucor and Rhizopus are also similar in several characteristics. They are saprophytic colonizers, filamentous, and have a stiff cell wall but vary in possessing sporangiospores and a stolon [28]. Also, Aspergillus and Candida have almost identical morphological features but distinct pathways for causing illness. Aspergillus spp. infects respiratory and nasal tissues, whereas Candida spp. attacks mainly endothelium and epithelial cells. The symptoms are significantly different in this situation because Aspergillus spp. has the most substantial match with the SARS-CoV-2 pathways and remarkably impacted the health of COVID-19 patients [29, 30].

Table 1 Morphological features, pathogenicity, clinical findings, and laboratory diagnosis of the fungi causing coinfection with SARS-CoV-2

The global fungal outbreaks in COVID-19 patients

Although fungal disease outbreaks are rare, opportunistic fungi take advantage of the weakened immune system of COVID-19 patients [15, 31]. Geological differences have influenced the occurrences of fungal coinfection. Peng et al. [18] reported that the fungal coinfection rate was significantly higher in patients from Asia than non-Asian patients. With the uprising second wave of COVID-19, a rare fungal disease mucormycosis caused by Mucor spp. happened in India with a high mortality rate [32]. Though India dealt with the severity, other regions, including the USA, the UK, Australia, France, Brazil, and Mexico, also reported having black fungus cases [33]. On May 25, 2021, two black fungus cases in Dhaka, Bangladesh, were found in individuals recovered from COVID-19. In July and August 2021, another two patients aged 40 to 60 were also diagnosed with black fungus. They were at their post-recovery stage of COVID-19, and their second COVID-19 tests were also negative. Interestingly, one of them even received two doses of the COVID-19 vaccine [34]. Moreover, John et al. [31] have reviewed 41 case reports of COVID-19 and mucormycosis, where 29 were recorded from India. Until July 21, 2021, over 45,374 mucormycosis cases have been reported in India, whereas 4,322 have died [32, 35]. Symptoms of mucormycosis developed between 6 and 24 days from the onset of disease, and a six-day delay of treatment could lead to mortality up to 66% [36, 37]. Nevertheless, some individuals who did not have diabetes and took steroids were also diagnosed with mucormycosis, indicating that COVID-19 is a risk factor for mucormycosis [38].

Fungal coinfections, including 40 Candida auris-infected cases in the USA, Candida glabrata- and Candida albicans-associated cases in China, Aspergillus flavus- and Aspergillus fumigatus-related infections have also been documented in Europe [39]. In addition, between January and March 2020, 8 out of 104 COVID-19 patients infected with IPA have been found in China [40]. According to some other reports, the morbidity rate for IPA coinfection with COVID-19 patients was 20.6% in Belgium, 19.6% in the Netherlands, 33.3% in France, and 26% in Germany [41, 42]. A study found that when candidemia occurs with SARS-CoV-2, the mortality rate was 83.3%, even though the proper antifungal treatment was given to the patients [43]. In another study conducted in Colombia, 20 cases with around 30 days of observation while receiving antifungal therapy before achieving fungemia and taking up steroids due to COVID-19 came up with a 60% mortality rate [44]. Fekkar et al. conducted a study among 2723 hospitalized COVID-19 patients, whereas eight were positive for CAPA, while the morbidity rate was 0.03% for hospitalized individuals and 3.3% for ICU patients. Shockingly, all eight patients with CAPA were died [41]. Furthermore, an observational study on CAPA conducted by Nasir et al. in Pakistan found that the mortality rate was 44% [42].

An overview of how fungi take the opportunity of the hampered immune system caused by SARS-CoV-2

SARS-CoV-2 anticipates the presence of angiotensin-converting enzyme-2 (ACE-2) receptor in the lung tissue, hence entering the lung cells with the help of furin. This entry site also provides virus stability [12]. The ACE-2 receptor has a downregulated expression in lung cells, leading to renin–angiotensin dysfunction in conjunction with acute lung injury. Followed by vascular leakage, inflammatory programmed cell death called pyroptosis stimulates inflammatory response locally. The result of pyroptosis is the secretion of different cytokines and chemokines in the blood, such as IL-1β, IL-6, IFN-γ, IFNγ-produced protein 10 (IP-10), and monocyte chemoattractant protein 1 (MCP1) [45]. SARS-CoV-2 has six ORFs in common with all coronaviruses, including ORF1a and ORF1b, which span more than two-thirds of the genome [46]. The ORF codes for nonstructural proteins (Nsps), accessory, and structural proteins. The papain-like protease (Nsp3), chymotrypsin-like, 3C-like or main protease (Nsp5), helicase (Nsp13), and RNA-dependent RNA polymerase (Nsp12) are believed to be involved in SARS-CoV-2 transcription and replication. Spike surface glycoprotein (S), membrane nucleocapsid protein (N), an envelope protein (E), and auxiliary proteins expressed by ORFs are four vital structural proteins in addition to Nsps [12]. While infected with SARS-CoV-2, Nsp3 of the virus leads to the cleavage of ISG15 from IRF3, therefore attenuating the type I IFN. Moreover, SARS-CoV-2 Nsp1 proteins suppress IFN responses. Regarding IRF3 nuclear translocation, SARS-CoV-2 ORF3b has a higher inhibitory impact [47].

Furthermore, SARS-CoV-2 ORF6 inhibits and prevents the generation of interferons (IFNs); consequently, the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway becomes shut off [47]. Contrarily, when viral protein interacts with macrophages, it causes the production of cytokines such as IL-6, IL-10, IL-18, IL-12, IL1, and TNF-α [48]. The antigen-presenting cells (APC) present viral peptides to T-lymphocytes with the help of the MHC II complex (major histocompatibility complex class II), which conducts adaptive immune response by generating compromised T memory cells and releasing IFN-γ, IL-10, IL-17, and other chemokines subsequently. Survivors of COVID-19 are hence possessed with several cytokines and chemokines during infection called “cytokine storm” by dint of uncontrolled immune defense. Tocilizumab, infliximab, and serine protease inhibitors are applied to block the secretion of IL-6 and TNF-α and NF-κB expression to control hyper inflammation [49]. T cells and macrophages produce a smaller proportion of type II IFNs than natural killer cells. Type II IFNs induce apoptosis in infected cells and activate macrophages, natural killer cells, and T lymphocytes. Both type I and type II IFNs levels are decreased after in vitro stimulation of immune cells from COVID-19 patients is correlated with increasing disease extremity [50].

Fungal spores are first confronted by the first-line defense of the host, which subsequently results in an innate immune response. In conventional cases, fungal spores are engulfed by macrophages, killed by neutrophils, and attached to dendritic cells through receptor dectine-1. However, moving to the presentation of the fungal pathogen to APC, they faced IFN-γ or IL-17 (Th-17) that clear out them from the host cell. Host cells are embedded with many cytokines, mainly TNF-α, IL-1, and IL-6 [51]. Fungi are prone to be distinguished by the action of IFN-γ or IL-17 provided by T cells. Given impaired T cells and fewer other lymphocytes, fungi could not be eliminated from an immunosuppressed patient, especially if infected with SARS-CoV-2. To this extent, an opportunistic fungal coinfection in immunocompromised SARS-CoV-2 patients may result in short survival or cure [16] (Fig. 1).

Fig. 1
figure 1

An overview of how fungi take the chances of the hampered immune system caused by SARS-CoV-2. Innate immune response in SARS-CoV-2 infection: SARS-CoV-2 enter the host cell through the attachment of viral spike (S) protein to ACE-2 (angiotensin-converting enzyme-2) receptor on the cell membrane (1). Then ssRNA virus is reassembled to the dsRNA viral genome (2). TLR-3 (Toll-like receptor-3) mutation stops the NF-κβ (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway and prevents the release of cytokines and chemokines (3). Macrophage releases IL-6, IL-10, IL-12, IL-18, IL1-β, and TNF-α (4). Antigen-presenting cells (APC) present MHC II (major histocompatibility complex II) peptide complex on T cells (5, 6). Adaptive immune response in SARS-CoV-2 infection: TH1/CD8 + and TH2/CD4 + release IFN-γ, TNF-α, IL-10, and IL-17 (7, 8). TH2 releases antibodies followed by activating B-cell (9, 10). Antibodies activate NK (natural killer) cells to release cytokines and chemokines (11, 12). Innate immune response in fungal infection after SARS-CoV-2 infection: Fungal complement protein stops the release of IL-6 and TGF-β (13). Fungal pathogens activate neutrophils (14). Pathogen attaches by dectin-1 in dendritic cells, and destructed immune system fails to release cytokines (15, 16). Pathogen escapes and subsequently presents on APC (antigen-presenting cells) with the help of the MHC II peptide complex to activate T cells (17, 18). Adaptive immune response in fungal infection after SARS-CoV-2 infection: Impaired adaptive immune response having cytokines from the “cytokine storm” results in the blockage of the proliferation of T cell into TH1/CD8 + and TH2/CD4 + (19, 20)

Control and prevention of fungal infections in COVID-19 patients

Prolonged hospitalization, long-time illness, lack of surveillance and early diagnosis, clinical mismanagement, and antibiotics that suppress the defense system of COVID-19 patients trigger the fungal coinfection [52]. For instance, bronchoscopy performed on COVID-19 patients is an approach of aerosol generation, which could affect immunocompromised patients with fungal spores. The detection of galactomannan (a polysaccharide antigen of Aspergillus spp. cell wall) from bronchoalveolar lavage fluid is quite a functional and prompt method to detect invasive aspergillosis in immunocompromised patients [53]. In addition, PCR tests could also be helpful in early diagnosis other than galactomannan tests [40]. For detection and control of the Candida spp., screening could be performed regularly to determine its risk factors and revaluate treatment protocol routinely [54].

Voriconazole is considered a preliminary antifungal treatment that works effectively with amphotericin B deoxycholate. Isavuconazole is another antifungal drug that holds the same activity as voriconazole. Echinocandins with azole work rapidly against invasive aspergillosis. Several drugs are still under clinical trials, including the inositol acylase inhibitor fosmanogepix against invasive aspergillosis and oral triterpenoid beta-glucan inhibitor ibrexafungerp against invasive aspergillosis and candidiasis. Although there is no specific time limit for therapy for fungal coinfection, experts suggest taking the drugs for 6 to 12 weeks as a course [55].

Conclusions

The severity of SARS-CoV-2 complexities rises with coinfection of fungi during or after SARS-CoV-2 infection. According to the assessment of fatality and number of illnesses, it may not be wrong to say that if pre-diagnosis does not happen or patients remain unchecked for fungal or other coinfection, another threat will emerge in the coming days. It has already been shown that mortality due to fungal coinfection does not change significantly, even if antifungal treatment is taking place to cure the disease. Pre-laboratory diagnosis should be given utmost attention to avoid a worsening condition. Several cautions should be maintained to limit the spread of fungal spores, including wearing masks, sanitizing, and maintaining cleanliness. Changing diet and acquiring the habit of sanitization could help to boost immunity.

Availability of data and materials

Not applicable.

Abbreviations

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus-2

COVID-19:

Coronavirus disease 2019

CNS:

Central nervous system

ARDS:

Acute respiratory distress syndrome

ICU:

Intensive care units

Th:

T helper cell

IL:

Interleukin

CAPA:

COVID-19-associated pulmonary aspergillosis

IPA:

Invasive pulmonary aspergillosis

ACE-2:

Angiotensin-converting enzyme-2

IFN:

Interferon

IP-10:

IFNγ-produced protein 10

MCP1:

Monocyte chemoattractant protein 1

Nsps:

Nonstructural proteins

ORF:

Open reading frame

ISG15:

Interferon-stimulated gene15

IRF3:

Interferon regulatory factor 3

TNF:

Tumor necrosis factor

APC:

Antigen-presenting cells

MHC:

Major histocompatibility complex

NF-κB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

References

  1. Saxena SK, Kumar S, Maurya VK, Sharma R, Dandu HR, Bhatt MLB. (2020) Current insight into the novel coronavirus disease 2019 (COVID-19). Coronavirus Disease 2019 (COVID-19)2020. p. 1–8.

  2. Sharma O, Sultan AA, Ding H, Triggle CR (2020) A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 11:585354. https://doi.org/10.3389/fimmu.2020.585354

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Ekiz T, Pazarlı AC (2020). Relationship between COVID-19 and obesity. Diabet Metab Syndrome.14(5):761–3. https://doi.org/10.1016/j.dsx.2020.05.047

  4. Akpek M (2021) Does COVID-19 cause hypertension? Angiology. https://doi.org/10.1177/00033197211053903

    Article  PubMed  Google Scholar 

  5. Aouissi HA, Belhaouchet I (2021) What about rheumatic diseases and COVID-19? New Microb New Infect 41:100846. https://doi.org/10.1016/j.nmni.2021.100846

    CAS  Article  Google Scholar 

  6. Bishburg E, Okoh A, Nagarakanti SR, Lindner M, Migliore C, Patel P (2021) Fungemia in COVID-19 ICU patients, a single medical center experience. J Med Virol. 93(5):2810–4. https://doi.org/10.1002/jmv.26633

    CAS  Article  PubMed  Google Scholar 

  7. Landstra CP, de Koning EJP (2021) COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol. https://doi.org/10.3389/fendo.2021.649525

    Article  Google Scholar 

  8. CDC (2021) Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States. https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e2.htm. Accessed 22 January 2021

  9. Chatterjee D, Tauzin A, Laumaea A, Gong SY, Bo Y, Guilbault A et al (2022) Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses. https://doi.org/10.3390/v14010144

    Article  PubMed  PubMed Central  Google Scholar 

  10. Aouissi HA (2021) Algeria’s preparedness for Omicron variant and for the fourth wave of COVID-19. Glob Health Med. 3(6):413–4. https://doi.org/10.35772/ghm.2021.01117

  11. Paredes MI, Lunn SM, Famulare M, Frisbie LA, Painter I, Burstein R, et al. (2022). Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. medRxiv. https://doi.org/10.1101/2021.09.29.21264272

  12. Kumar S, Nyodu R, Maurya VK, Saxena SK (2020) (2020) Host immune response and immunobiology of human SARS-CoV-2 infection. In: Saxena SK (ed) Coronavirus disease 2019 (COVID-19): epidemiology, pathogenesis, diagnosis, and therapeutics. Springer Singapore, Singapore, pp 43–53

    Chapter  Google Scholar 

  13. Nargesi S, Bongomin F, Hedayati MT (2021) The impact of COVID-19 pandemic on AIDS-related mycoses and fungal neglected tropical diseases: Why should we worry? PLoS Negl Trop Dis 15(2):e0009092. https://doi.org/10.1371/journal.pntd.0009092

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Salehi M, Ahmadikia K, Badali H, Khodavaisy S (2020) Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia 185(4):607–611. https://doi.org/10.1007/s11046-020-00472-7

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. CDC (2021) Fungal diseases and COVID-19. https://www.cdc.gov/fungal/covid-fungal.html. Accessed 22 March 2022

  16. Drummond RA, Franco LM, Lionakis MS (2018) Human CARD9: a critical molecule of fungal immune surveillance. Front Immunol 9:1836. https://doi.org/10.3389/fimmu.2018.01836

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Nasab MG, Saghazadeh A, Rezaei N (2020) SARS-CoV-2-A tough opponent for the immune system. Arch Med Res 51(6):589–592. https://doi.org/10.1016/j.arcmed.2020.05.020

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Peman J, Ruiz-Gaitan A, Garcia-Vidal C, Salavert M, Ramirez P, Puchades F et al (2020) Fungal co-infection in COVID-19 patients: should we be concerned? Revista iberoamericana de micologia. 37(2):41–6. https://doi.org/10.1016/j.riam.2020.07.001

    Article  PubMed  PubMed Central  Google Scholar 

  19. CDC (2022) Fungal diseases and COVID-19. https://www.cdc.gov/fungal/covid-fungal.html?fbclid=IwAR1-yqAL9IuHfY9s5YycFb_eoS6GRbOkqtjqYA-Jyzs59Q19-o9s99uW_M0#:~:text=COVID%2D19%2Dassociated%20fungal%20infections,to%20severe%20illness%20and%20death.&text=Symptoms%20of%20certain%20fungal%20diseases,cough%2C%20and%20shortness%20of%20breath.&text=Some%20patients%20can%20have%20COVID,infection%20at%20the%20same%20time. Accessed 22 March 2022.

  20. Peng J, Wang Q, Mei H, Zheng H, Liang G, She X, et al. (2021). Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis. Aging (Albany NY) 13(6):7745–57. https://doi.org/10.18632/aging.202742

  21. Coskun AS, Durmaz SO (2021) Fungal infections in COVID-19 intensive care patients. Pol J Microbiol 70(3):395–400. https://doi.org/10.33073/pjm-2021-039

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hagen A (2021) COVID-19-associated mucormycosis: triple threat of the pandemic. https://asm.org/Articles/2021/July/COVID-19-Associated-Mucormycosis-Triple-Threat-of. Accessed 22 March 2022.

  23. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B (2020) Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 8(6):e48–e49. https://doi.org/10.1016/s2213-2600(20)30237-x

    CAS  Article  PubMed  Google Scholar 

  24. Antinori S, Rech R, Galimberti L, Castelli A, Angeli E, Fossali T et al (2020) Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: a diagnostic challenge. Travel Med Infect Dis 38:101752. https://doi.org/10.1016/j.tmaid.2020.101752

    Article  PubMed  PubMed Central  Google Scholar 

  25. Koehler P, Cornely OA, Bottiger BW, Dusse F, Eichenauer DA, Fuchs F et al (2020) COVID-19 associated pulmonary aspergillosis. Mycoses 63(6):528–534. https://doi.org/10.1111/myc.13096

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Menon AA, Berg DD, Brea EJ, Deutsch AJ, Kidia KK, Thurber EG et al (2020) A case of COVID-19 and pneumocystis jirovecii coinfection. Am J Respir Crit Care Med 202(1):136–138. https://doi.org/10.1164/rccm.202003-0766LE

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. Lackner M, Caramalho R, Lass-Flörl C (2014) Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol 9(5):683–95. https://doi.org/10.2217/fmb.14.23

    CAS  Article  PubMed  Google Scholar 

  28. Bartnicki-Garcia S, Nickerson WJ (1962) Isolation, composition, and structure of cell walls of filamentous and yeast-like forms of Mucor rouxii. Biochimica et biophysica acta. 58:102–19. https://doi.org/10.1016/0006-3002(62)90822-3

    CAS  Article  PubMed  Google Scholar 

  29. Marr KA, Patterson T, Denning D (2002) Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N Am 16(4):875–94. https://doi.org/10.1016/s0891-5520(02)00035-1

    Article  Google Scholar 

  30. Mba IE, Nweze EI (2020) Mechanism of Candida pathogenesis: revisiting the vital drivers. Eur J Clin Microbiol Infect Dis 39(10):1797–1819. https://doi.org/10.1007/s10096-020-03912-w

    Article  PubMed  Google Scholar 

  31. John TM, Jacob CN, Kontoyiannis DP (2021) When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel). https://doi.org/10.3390/jof7040298

    Article  Google Scholar 

  32. Aljazeera. (2021) ‘Black fungus’ new scare in India as second COVID wave ebbs. https://www.aljazeera.com/news/2021/6/8/black-fungus-new-scare-in-india-as-second-covid-wave-ebbs. Accessed 19 August 2021

  33. Manas Mishra KD (2021) ‘Black fungus’ complication adds to India’s COVID woes. https://www.reuters.com/world/india/black-fungus-complication-adds-indias-covid-woes-2021-05-10/. Accessed 10 May 2021

  34. Welfare MoHaF (2021) First black fungus patient identified in Chattogram. http://www.mohfw.gov.bd/. Accessed 20 January 2022

  35. India TTO (2021) India reports 45,374 Black fungus cases, 4,332 deaths so far 2021. https://timesofindia.indiatimes.com/india/india-reports-45374-black-fungus-cases-4332-deaths-so-far-says-health-ministry/articleshow/84640357.cms. Accessed 24 March 2022.

  36. Rocha ICN, Hasan MM, Goyal S, Patel T, Jain S, Ghosh A et al (2021) COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Trop Med Int Health 26(9):1016–1018. https://doi.org/10.1111/tmi.13641

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Bhogireddy R, Krishnamurthy V, Jabaris SS, Pullaiah CP, Manohar S (2021) Is Mucormycosis an inevitable complication of Covid-19 in India? Braz J Infect Dis 25(3):101597. https://doi.org/10.1016/j.bjid.2021.101597

    Article  PubMed  PubMed Central  Google Scholar 

  38. Palanisamy PR, Elango D (2022) COVID19 associated mucormycosis: a review. J Fam Med Primary Care 11(2):418–23. https://doi.org/10.4103/jfmpc.jfmpc_1186_21

    Article  Google Scholar 

  39. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG (2020) COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med 202(1):132–135. https://doi.org/10.1164/rccm.202004-1038LE

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lai CC, Yu WL (2021) COVID-19 associated with pulmonary aspergillosis: A literature review. J Microbiol Immunol Infect 54(1):46–53. https://doi.org/10.1016/j.jmii.2020.09.004

    CAS  Article  PubMed  Google Scholar 

  41. Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, Kontoyiannis DP, Lamoth F (2021) COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? Clin Microbiol Infect 27(9):1376–1378. https://doi.org/10.1016/j.cmi.2021.06.025

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. Nasir N, Farooqi J, Mahmood SF, Jabeen K (2020) COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses 63(8):766–770. https://doi.org/10.1111/myc.13135

    CAS  Article  PubMed  Google Scholar 

  43. Bhatt K, Agolli A, Patel MH, Garimella R, Devi M, Garcia E, et al. (2021). High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 9(1):e126. https://doi.org/10.15190/d.2021.5

  44. Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labiosa AL, Alvarez-Moreno C (2020) Candida auris: a latent threat to critically ill patients with COVID-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1595

    Article  PubMed  PubMed Central  Google Scholar 

  45. Atal S, Fatima Z (2020) IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med 34(4):223–231. https://doi.org/10.1007/s40290-020-00342-z

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. Jungreis I, Sealfon R, Kellis M (2021) SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat Commun 12(1):2642. https://doi.org/10.1038/s41467-021-22905-7

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  47. Kim YM, Shin EC (2021) Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med 53(5):750–760. https://doi.org/10.1038/s12276-021-00592-0

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C (2020) Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 5(1):84. https://doi.org/10.1038/s41392-020-0191-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. Ruetsch C, Brglez V, Cremoni M, Zorzi K, Fernandez C, Boyer-Suavet S et al (2020) Functional exhaustion of Type I and II interferons production in severe COVID-19 patients. Front Med (Lausanne). 7:603961. https://doi.org/10.3389/fmed.2020.603961

    Article  PubMed  Google Scholar 

  51. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827. https://doi.org/10.3389/fimmu.2020.00827

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. Cimolai N (2021) The complexity of co-infections in the era of COVID-19. SN Compr Clin Med. https://doi.org/10.1007/s42399-021-00913-4

    Article  PubMed  PubMed Central  Google Scholar 

  53. Lansbury L, Lim B, Baskaran V, Lim WS (2020) Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 81(2):266–275. https://doi.org/10.1016/j.jinf.2020.05.046

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. Agrifoglio A, Cachafeiro L, Figueira JC, Añón JM, García de Lorenzo A (2020) Critically ill patients with COVID-19 and candidaemia: we must keep this in mind. J Mycol Med. 30(4):101012. https://doi.org/10.1016/j.mycmed.2020.101012

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  55. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. (2021). Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. The Lancet. Infect Dis 21(6):e149-e62. https://doi.org/10.1016/s1473-3099(20)30847-1

  56. Davis CP (2021) Mucormycosis: types, symptoms, diagnosis and treatment. https://www.medicinenet.com/mucormycosis/article.htm. Accessed 29 September 2021.

  57. Kim MJ, Park PW, Ahn JY, Kim KH, Seo JY, Jeong JH et al (2014) Fatal pulmonary mucormycosis caused by Rhizopus microsporus in a patient with diabetes. Ann Lab Med 34(1):76–9. https://doi.org/10.3343/alm.2014.34.1.76

    Article  PubMed  Google Scholar 

  58. Hassan MIA, Voigt K (2019) Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol. 57(Supplement_2):S245-S56.

  59. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. (2007). Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (Reading, England).153(Pt 6):1677–92.https://doi.org/10.1099/mic.0.2007/007641-0

  60. Rudramurthy SM, Singh S (2020) Candida infections in immunocompetent hosts: pathogenesis and diagnosis. Curr Fung Infect Rep 14(3):233–245. https://doi.org/10.1007/s12281-020-00392-5

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

MMR has given the concept of the review. NB, SW, AT, and MHUM wrote the manuscript’s first draft. MMR and AT revised and edited the draft. All authors read and approved the final manuscript for publication.

Corresponding author

Correspondence to Md. Mijanur Rahman.

Ethics declarations

Ethics approval and consent to participate.

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that there are no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baten, N., Wajed, S., Talukder, A. et al. Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients. Beni-Suef Univ J Basic Appl Sci 11, 64 (2022). https://doi.org/10.1186/s43088-022-00245-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43088-022-00245-9

Keywords

  • COVID-19
  • SARS-CoV-2
  • Fungal coinfection
  • Mucormycosis
  • IPA
  • CAPA